Back to Search
Test Name REF LAB FISH EGFR
Orderable CPT -
OVT 123002548
Synonyms -
Result Test Name CLINICAL INDICATION:
Laboratory QUEST LAB
Result Test Code 123012211
Laboratory Test Name QUEST FISH EGFR
Reportable Test Name -
Result LOINC 55752-0
Collection Container PATH CONTAINER
Units -
Collection Requirements Preferred Specimen(s) Formalin-fixed paraffin-embedded tissue Alternative Specimen(s) 5x5 mm tumor tissue submitted in culture transport medium 4-5 microns sections on charged slides (x5) Collection Instructions For EGRF determination in solid tumors only biopsies with histologically proven tumor involvement should be tested. Samples that can be tested include tumor biopsy in tissue culture media formalin-fixed paraffin-embedded block or a minimum of 5 charged/+ slides from formalin-fixed paraffin- embedded tissue. Specimen must be fixed in 10% neutral buffered formalin. Fixation between 6 and 48 hours is recommended. Pathology report must accompany paraffin block or slides.
Container Temp Room Temperature (1)
Container Volume -
Test Info FISH EGFR - The epidermal growth factor receptor (EGFR) is a cellular transmembrane receptor with tyrosine kinase enzymatic activity that plays a key role in human cancer. EGFR-dependent signaling is involved in cancer cell proliferation apoptosis angiogenesis invasion and metastasis. Targeting the EGFR is a valuable molecular approach to cancer therapy. Lung Cancer: Epidermal growth factor receptor (EGFR) Inhibitors have shown promising results in patients with advanced non-small cell lung cancers (NSCLC) who previously have failed on chemotherapy. Colorectal Cancer: The antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies cetuximab and pantiumamab have good clinical activity in about 10% of patients with metastatic colorectal cancer that is resistant to chemotherapy. Breast Cancer: EGFR levels were examined by radioligand binding assays in 846 patients with invasive breast cancer. The median follow-up period was 50 months. There was a wide variablility of EGRF levels among the studied tumors (0.01-403 fmol/mg protein).
Shipping Instructions Transport Container Formalin-fixed paraffin-embedded tissue block Transport Temperature Room temperature Specimen Stability Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not reject.
Result Test Name QUEST FISH EGFR
Laboratory QUEST LAB
Result Test Code 123924774
Laboratory Test Name QUEST FISH EGFR
Reportable Test Name -
Result LOINC -
Collection Container PATH CONTAINER
Units -
Collection Requirements Preferred Specimen(s) Formalin-fixed paraffin-embedded tissue Alternative Specimen(s) 5x5 mm tumor tissue submitted in culture transport medium 4-5 microns sections on charged slides (x5) Collection Instructions For EGRF determination in solid tumors only biopsies with histologically proven tumor involvement should be tested. Samples that can be tested include tumor biopsy in tissue culture media formalin-fixed paraffin-embedded block or a minimum of 5 charged/+ slides from formalin-fixed paraffin- embedded tissue. Specimen must be fixed in 10% neutral buffered formalin. Fixation between 6 and 48 hours is recommended. Pathology report must accompany paraffin block or slides.
Container Temp Room Temperature (1)
Container Volume -
Test Info FISH EGFR - The epidermal growth factor receptor (EGFR) is a cellular transmembrane receptor with tyrosine kinase enzymatic activity that plays a key role in human cancer. EGFR-dependent signaling is involved in cancer cell proliferation apoptosis angiogenesis invasion and metastasis. Targeting the EGFR is a valuable molecular approach to cancer therapy. Lung Cancer: Epidermal growth factor receptor (EGFR) Inhibitors have shown promising results in patients with advanced non-small cell lung cancers (NSCLC) who previously have failed on chemotherapy. Colorectal Cancer: The antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies cetuximab and pantiumamab have good clinical activity in about 10% of patients with metastatic colorectal cancer that is resistant to chemotherapy. Breast Cancer: EGFR levels were examined by radioligand binding assays in 846 patients with invasive breast cancer. The median follow-up period was 50 months. There was a wide variablility of EGRF levels among the studied tumors (0.01-403 fmol/mg protein).
Shipping Instructions Transport Container Formalin-fixed paraffin-embedded tissue block Transport Temperature Room temperature Specimen Stability Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not reject.
Result Test Name QUEST SPECIMEN TYPE/SOURCE
Laboratory QUEST LAB
Result Test Code 123924859
Laboratory Test Name QUEST FISH EGFR
Reportable Test Name -
Result LOINC 31208-2
Collection Container PATH CONTAINER
Units -
Collection Requirements Preferred Specimen(s) Formalin-fixed paraffin-embedded tissue Alternative Specimen(s) 5x5 mm tumor tissue submitted in culture transport medium 4-5 microns sections on charged slides (x5) Collection Instructions For EGRF determination in solid tumors only biopsies with histologically proven tumor involvement should be tested. Samples that can be tested include tumor biopsy in tissue culture media formalin-fixed paraffin-embedded block or a minimum of 5 charged/+ slides from formalin-fixed paraffin- embedded tissue. Specimen must be fixed in 10% neutral buffered formalin. Fixation between 6 and 48 hours is recommended. Pathology report must accompany paraffin block or slides.
Container Temp Room Temperature (1)
Container Volume -
Test Info FISH EGFR - The epidermal growth factor receptor (EGFR) is a cellular transmembrane receptor with tyrosine kinase enzymatic activity that plays a key role in human cancer. EGFR-dependent signaling is involved in cancer cell proliferation apoptosis angiogenesis invasion and metastasis. Targeting the EGFR is a valuable molecular approach to cancer therapy. Lung Cancer: Epidermal growth factor receptor (EGFR) Inhibitors have shown promising results in patients with advanced non-small cell lung cancers (NSCLC) who previously have failed on chemotherapy. Colorectal Cancer: The antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies cetuximab and pantiumamab have good clinical activity in about 10% of patients with metastatic colorectal cancer that is resistant to chemotherapy. Breast Cancer: EGFR levels were examined by radioligand binding assays in 846 patients with invasive breast cancer. The median follow-up period was 50 months. There was a wide variablility of EGRF levels among the studied tumors (0.01-403 fmol/mg protein).
Shipping Instructions Transport Container Formalin-fixed paraffin-embedded tissue block Transport Temperature Room temperature Specimen Stability Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not reject.